(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included a session on the risk stratification of prostate cancer and a presentation by medical oncologist Dr. Alicia Morgans discussing the incorporation of molecular markers and genomic studies into advanced prostate cancer therapy. Dr. Morgans notes that according to the NCCN Guidelines Version 2.2022 for prostate cancer, germline testing is specifically recommended for patients with metastatic, regional (node positive), very-high risk localized, and high-risk localized prostate cancer. Additionally, germline testing may be considered in patients with a personal history of prostate cancer and those with: